Selective digestive decontamination in multiple trauma patients: Cost and efficacy
- Cite this article as:
- Langlois-Karaga, A., Bues-Charbit, M., Davignon, A. et al. Pharm World Sci (1995) 17: 12. doi:10.1007/BF01875552
- 24 Views
A double-blind randomized placebo-controlled study was carried out to evaluate the efficacy and the cost of selective digestive decontamination (SDD) to prevent nosocomial pneumonia in multiple-trauma patients. Nosocomial infections, particularly pneumonia, were more frequent in the placebo group. The most common infectious agent wasStaphylococcus: Staphylococcus aureus in the placebo group andStaphylococcus epidermidis in the SDD group. Methicillin-resistantStaphylococcus epidermidis was detected more often in the SDD group. No methicillin-resistantStaphylococcus aureus was observed in this study. Fewer patients in the SDD group required antibiotherapy. SDD resulted in a saving of about 41% in drug expenditure.